On February 4, Merck released financial ... especially given the significant investments the Rahway, New Jersey-based company has made in developing its oncology franchise over the past year ...

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end ...

PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

According to the World Health Organization (WHO), cancer remains one ... a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK), based in Rahway, New Jersey, is a leading American multinational ...

The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ...

Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIR ...

The company focuses on therapy areas such as oncology, diabetes, and vaccines and has recently inaugurated a new technology center in Hyderabad. Reuters FILE PHOTO: The Merck logo is seen at a gate to ...

It engages the patient’s immune system to fight off cancer by mounting a targeted response against tumors. The phase 2 trial investigates EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, ...

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with ...